This review discusses how the treat-to-target strategy improves disease activity and organ protection in systemic lupus erythematosus.
This review discusses indices used to assess systemic lupus erythematosus (SLE) activity. Particular attention is given to the definitions of low disease activity and remission in SLE, first clearly formulated in 2016 and 2021, respectively, and to the treat-to-target (T2T) strategy aimed at reducing disease activity, preventing organ damage, and minimizing glucocorticoid use.
No takes yet. Share an insight, caveat, or question.
Sholkina et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: